Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Non-Hodgkin-Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT00002485
What this trial is testing

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Who this might be right for
Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+8 more
Children's Oncology Group 359
Testing effectiveness (Phase 2)Ended earlyNCT05588440
What this trial is testing

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Malignancies
Oncternal Therapeutics, Inc 9
Testing effectiveness (Phase 2)Looking for participantsNCT06321289
What this trial is testing

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)WithdrawnNCT03999658
What this trial is testing

STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B Cell LymphomaBiliary Tract Cancer+1 more
Sorrento Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Testing effectiveness (Phase 2)Study completedNCT03196830
What this trial is testing

CAR-T for R/R B-NHL

Who this might be right for
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin LymphomaCAR - T CD19/CD20/CD22/CD30
The First Affiliated Hospital of Soochow University 168
Testing effectiveness (Phase 2)Looking for participantsNCT04150497
What this trial is testing

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Cellectis S.A. 52
Large-scale testing (Phase 3)Looking for participantsNCT06561048
What this trial is testing

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc. 150
Large-scale testing (Phase 3)Looking for participantsNCT07377578
What this trial is testing

Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD. 394
Early research (Phase 1)Looking for participantsNCT06326008
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in Relapse
Beijing GoBroad Hospital 48
Early research (Phase 1)Study completedNCT04317885
What this trial is testing

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Who this might be right for
Non-Hodgkin's B-cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine 25
Testing effectiveness (Phase 2)Study completedNCT00426855
What this trial is testing

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Peter Moosmann 12
Early research (Phase 1)Looking for participantsNCT05794958
What this trial is testing

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Who this might be right for
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Stanford University 20
Testing effectiveness (Phase 2)UnknownNCT00385125
What this trial is testing

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Who this might be right for
Lymphoma, High-Grade
University of Magdeburg 30
Not applicableApproved For MarketingNCT04300803
What this trial is testing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Who this might be right for
DLBCL
MorphoSys AG
Testing effectiveness (Phase 2)UnknownNCT04296786
What this trial is testing

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Who this might be right for
Cutaneous T-cell Lymphoma
Peking Union Medical College Hospital 52
Early research (Phase 1)Ended earlyNCT03778073
What this trial is testing

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Who this might be right for
B-cell Non Hodgkin LymphomaRichter's Transformation
TG Therapeutics, Inc. 18
Early research (Phase 1)Looking for participantsNCT06879340
What this trial is testing

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Who this might be right for
B-Cell Non-Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Kansas Medical Center 54
Testing effectiveness (Phase 2)UnknownNCT02851589
What this trial is testing

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Ended earlyNCT02875223
What this trial is testing

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinNeoplasms
Celgene 75
Next Page